You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

CLINICAL TRIALS PROFILE FOR HUMALOG


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Humalog

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT04161976 ↗ A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus Completed Eli Lilly and Company Phase 1 2019-12-27 The main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus. The study will investigate how the body processes the drug and how the drug affects the body. Information about side effects will be collected. The study will last from six to 12 weeks for each participant.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Humalog

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00046501 ↗ Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents Completed Sanofi Phase 3 2002-11-01 The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)
NCT00071448 ↗ Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population Completed Novo Nordisk A/S Phase 3 2002-06-01 This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00097071 ↗ Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents Completed Novo Nordisk A/S Phase 3 2004-10-01 This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.
NCT00115570 ↗ Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents Completed Sanofi Phase 3 2005-04-01 The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Humalog

Condition Name

Condition Name for Humalog
Intervention Trials
Diabetes Mellitus, Type 1 27
Type 1 Diabetes Mellitus 27
Diabetes Mellitus, Type 2 20
Type 2 Diabetes Mellitus 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Humalog
Intervention Trials
Diabetes Mellitus 122
Diabetes Mellitus, Type 1 76
Diabetes Mellitus, Type 2 40
Hyperglycemia 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Humalog

Trials by Country

Trials by Country for Humalog
Location Trials
United States 576
Germany 67
China 50
Spain 32
Canada 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Humalog
Location Trials
California 43
Texas 31
Florida 30
Georgia 29
Washington 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Humalog

Clinical Trial Phase

Clinical Trial Phase for Humalog
Clinical Trial Phase Trials
Phase 4 36
Phase 3 31
Phase 2/Phase 3 3
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Humalog
Clinical Trial Phase Trials
Completed 125
Not yet recruiting 8
Terminated 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Humalog

Sponsor Name

Sponsor Name for Humalog
Sponsor Trials
Eli Lilly and Company 53
Adocia 20
Sanofi 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Humalog
Sponsor Trials
Industry 140
Other 62
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.